Eribulin mesylate combined with local treatment for brain metastasis from breast cancer: Two case reports

Kyung Do Byun, Sung Gwe Ahn, Hyung Joo Baik, Anbok Lee, Ki Beom Bae, Min Sung An, Kwang Hee Kim, Jae Ho Shin, Ha Kyoung Park, Heunglae Cho, Joon Jeong, Tae Hyun Kim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The prognosis associated with brain metastasis arising from breast cancer is very poor. Eribulin is a microtubule dynamic inhibitor synthesized from halichondrin B, a natural marine product. In a phase III study (EMBRACE), eribulin improved overall survival in patients with heavily pretreated metastatic breast cancers. However, these studies included few patients with brain metastases. Metastatic brain tumors (MBT) were detected during first-line palliative chemotherapy in a 43-year-old woman with breast cancer metastasis to the lung and mediastinal nodes; the genetic subtype was luminal B-like human epidermal growth factor receptor 2 (HER2)-negative. Whole brain radiotherapy (WBRT) followed by eribulin treatment continuously decreased the size, and induced regression, of the MBT with systemic disease stability for 12 months. Another 48-year-old woman with metastatic breast cancer (HER2+ subtype) presented with MBT. Following surgical resection of the tumor, eribulin with concurrent WBRT showed regression of the MBT without systemic progression for 18 months.

Original languageEnglish
Pages (from-to)214-217
Number of pages4
JournalJournal of Breast Cancer
Volume19
Issue number2
DOIs
Publication statusPublished - 2016 Jun

Fingerprint

eribulin
Brain Neoplasms
Breast Neoplasms
Neoplasm Metastasis
Brain
Radiotherapy
Therapeutics
Microtubules
Drug Therapy
Lung
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Byun, Kyung Do ; Ahn, Sung Gwe ; Baik, Hyung Joo ; Lee, Anbok ; Bae, Ki Beom ; An, Min Sung ; Kim, Kwang Hee ; Shin, Jae Ho ; Park, Ha Kyoung ; Cho, Heunglae ; Jeong, Joon ; Kim, Tae Hyun. / Eribulin mesylate combined with local treatment for brain metastasis from breast cancer : Two case reports. In: Journal of Breast Cancer. 2016 ; Vol. 19, No. 2. pp. 214-217.
@article{141d8c6882784c83b2d8682c4b595ac0,
title = "Eribulin mesylate combined with local treatment for brain metastasis from breast cancer: Two case reports",
abstract = "The prognosis associated with brain metastasis arising from breast cancer is very poor. Eribulin is a microtubule dynamic inhibitor synthesized from halichondrin B, a natural marine product. In a phase III study (EMBRACE), eribulin improved overall survival in patients with heavily pretreated metastatic breast cancers. However, these studies included few patients with brain metastases. Metastatic brain tumors (MBT) were detected during first-line palliative chemotherapy in a 43-year-old woman with breast cancer metastasis to the lung and mediastinal nodes; the genetic subtype was luminal B-like human epidermal growth factor receptor 2 (HER2)-negative. Whole brain radiotherapy (WBRT) followed by eribulin treatment continuously decreased the size, and induced regression, of the MBT with systemic disease stability for 12 months. Another 48-year-old woman with metastatic breast cancer (HER2+ subtype) presented with MBT. Following surgical resection of the tumor, eribulin with concurrent WBRT showed regression of the MBT without systemic progression for 18 months.",
author = "Byun, {Kyung Do} and Ahn, {Sung Gwe} and Baik, {Hyung Joo} and Anbok Lee and Bae, {Ki Beom} and An, {Min Sung} and Kim, {Kwang Hee} and Shin, {Jae Ho} and Park, {Ha Kyoung} and Heunglae Cho and Joon Jeong and Kim, {Tae Hyun}",
year = "2016",
month = "6",
doi = "10.4048/jbc.2016.19.2.214",
language = "English",
volume = "19",
pages = "214--217",
journal = "Journal of Breast Cancer",
issn = "1738-6756",
publisher = "Korean Breast Cancer Society",
number = "2",

}

Byun, KD, Ahn, SG, Baik, HJ, Lee, A, Bae, KB, An, MS, Kim, KH, Shin, JH, Park, HK, Cho, H, Jeong, J & Kim, TH 2016, 'Eribulin mesylate combined with local treatment for brain metastasis from breast cancer: Two case reports', Journal of Breast Cancer, vol. 19, no. 2, pp. 214-217. https://doi.org/10.4048/jbc.2016.19.2.214

Eribulin mesylate combined with local treatment for brain metastasis from breast cancer : Two case reports. / Byun, Kyung Do; Ahn, Sung Gwe; Baik, Hyung Joo; Lee, Anbok; Bae, Ki Beom; An, Min Sung; Kim, Kwang Hee; Shin, Jae Ho; Park, Ha Kyoung; Cho, Heunglae; Jeong, Joon; Kim, Tae Hyun.

In: Journal of Breast Cancer, Vol. 19, No. 2, 06.2016, p. 214-217.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Eribulin mesylate combined with local treatment for brain metastasis from breast cancer

T2 - Two case reports

AU - Byun, Kyung Do

AU - Ahn, Sung Gwe

AU - Baik, Hyung Joo

AU - Lee, Anbok

AU - Bae, Ki Beom

AU - An, Min Sung

AU - Kim, Kwang Hee

AU - Shin, Jae Ho

AU - Park, Ha Kyoung

AU - Cho, Heunglae

AU - Jeong, Joon

AU - Kim, Tae Hyun

PY - 2016/6

Y1 - 2016/6

N2 - The prognosis associated with brain metastasis arising from breast cancer is very poor. Eribulin is a microtubule dynamic inhibitor synthesized from halichondrin B, a natural marine product. In a phase III study (EMBRACE), eribulin improved overall survival in patients with heavily pretreated metastatic breast cancers. However, these studies included few patients with brain metastases. Metastatic brain tumors (MBT) were detected during first-line palliative chemotherapy in a 43-year-old woman with breast cancer metastasis to the lung and mediastinal nodes; the genetic subtype was luminal B-like human epidermal growth factor receptor 2 (HER2)-negative. Whole brain radiotherapy (WBRT) followed by eribulin treatment continuously decreased the size, and induced regression, of the MBT with systemic disease stability for 12 months. Another 48-year-old woman with metastatic breast cancer (HER2+ subtype) presented with MBT. Following surgical resection of the tumor, eribulin with concurrent WBRT showed regression of the MBT without systemic progression for 18 months.

AB - The prognosis associated with brain metastasis arising from breast cancer is very poor. Eribulin is a microtubule dynamic inhibitor synthesized from halichondrin B, a natural marine product. In a phase III study (EMBRACE), eribulin improved overall survival in patients with heavily pretreated metastatic breast cancers. However, these studies included few patients with brain metastases. Metastatic brain tumors (MBT) were detected during first-line palliative chemotherapy in a 43-year-old woman with breast cancer metastasis to the lung and mediastinal nodes; the genetic subtype was luminal B-like human epidermal growth factor receptor 2 (HER2)-negative. Whole brain radiotherapy (WBRT) followed by eribulin treatment continuously decreased the size, and induced regression, of the MBT with systemic disease stability for 12 months. Another 48-year-old woman with metastatic breast cancer (HER2+ subtype) presented with MBT. Following surgical resection of the tumor, eribulin with concurrent WBRT showed regression of the MBT without systemic progression for 18 months.

UR - http://www.scopus.com/inward/record.url?scp=84977510993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977510993&partnerID=8YFLogxK

U2 - 10.4048/jbc.2016.19.2.214

DO - 10.4048/jbc.2016.19.2.214

M3 - Article

AN - SCOPUS:84977510993

VL - 19

SP - 214

EP - 217

JO - Journal of Breast Cancer

JF - Journal of Breast Cancer

SN - 1738-6756

IS - 2

ER -